Literature DB >> 32861279

Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Kevin Wang1, Xiangao Huang1, Maurizio Di Liberto1, Selina Chen-Kiang2.   

Abstract

Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma (MCL). Inhibition of CDK4/6 induces G1 arrest of MCL cells in patients, appearing to deepen and prolong the clinical response to partner agents. This article reviews aberrations of cell cycle genes in MCL cells and clinical trials of CDK4/6 inhibitors for MCL. Integrative longitudinal functional genomics is discussed as a strategy to discover genomic drivers for resistance in cancer cells and cancer-immune interactions that potentially contribute to the clinical response to palbociclib combination therapy in MCL.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDK4; Cyclin D1; Ibrutinib; Mantle cell lymphoma; Palbociclib; Rb; p16(INK4a)

Year:  2020        PMID： 32861279      PMCID： PMC7461610          DOI： 10.1016/j.hoc.2020.05.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  60 in total

1.  Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Authors:  C Schaffner; I Idler; S Stilgenbauer; H Döhner; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Authors:  David Martín-Garcia; Alba Navarro; Rafael Valdés-Mas; Guillem Clot; Jesús Gutiérrez-Abril; Miriam Prieto; Inmaculada Ribera-Cortada; Renata Woroniecka; Grzegorz Rymkiewicz; Susanne Bens; Laurence de Leval; Andreas Rosenwald; Judith A Ferry; Eric D Hsi; Kai Fu; Jan Delabie; Dennis Weisenburger; Daphne de Jong; Fina Climent; Sheila J O'Connor; Steven H Swerdlow; David Torrents; Sergi Beltran; Blanca Espinet; Blanca González-Farré; Luis Veloza; Dolors Costa; Estella Matutes; Reiner Siebert; German Ott; Leticia Quintanilla-Martinez; Elaine S Jaffe; Carlos López-Otín; Itziar Salaverria; Xose S Puente; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2018-12-11       Impact factor: 22.113

3.  Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

Authors:  Robert Kridel; Barbara Meissner; Sanja Rogic; Merrill Boyle; Adele Telenius; Bruce Woolcock; Jay Gunawardana; Christopher Jenkins; Chris Cochrane; Susana Ben-Neriah; King Tan; Ryan D Morin; Stephen Opat; Laurie H Sehn; Joseph M Connors; Marco A Marra; Andrew P Weng; Christian Steidl; Randy D Gascoyne
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

4.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.

Authors:  S Beà; M Ribas; J M Hernández; F Bosch; M Pinyol; L Hernández; J L García; T Flores; M González; A López-Guillermo; M A Piris; A Cardesa; E Montserrat; R Miró; E Campo
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

5.  Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

Authors:  Xiangao Huang; Maurizio Di Liberto; David Jayabalan; Jun Liang; Scott Ely; Jamieson Bretz; Arthur L Shaffer; Tracey Louie; Isan Chen; Sophia Randolph; William C Hahn; Louis M Staudt; Ruben Niesvizky; Malcolm A S Moore; Selina Chen-Kiang
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

6.  Postibrutinib outcomes in patients with mantle cell lymphoma.

Authors:  Peter Martin; Kami Maddocks; John P Leonard; Jia Ruan; Andre Goy; Nina Wagner-Johnston; Simon Rule; Ranjana Advani; David Iberri; Tycel Phillips; Stephen Spurgeon; Eliana Kozin; Katherine Noto; Zhengming Chen; Wojciech Jurczak; Rebecca Auer; Ewa Chmielowska; Stephan Stilgenbauer; Johannes Bloehdorn; Craig Portell; Michael E Williams; Martin Dreyling; Paul M Barr; Selina Chen-Kiang; Maurizio DiLiberto; Richard R Furman; Kristie A Blum
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

7.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Authors:  David W Fry; Patricia J Harvey; Paul R Keller; William L Elliott; Maryanne Meade; Erin Trachet; Mudher Albassam; XianXian Zheng; Wilbur R Leopold; Nancy K Pryer; Peter L Toogood
Journal:  Mol Cancer Ther       Date:  2004-11       Impact factor: 6.261

8.  CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Authors:  Jiehui Deng; Eric S Wang; Russell W Jenkins; Shuai Li; Ruben Dries; Kathleen Yates; Sandeep Chhabra; Wei Huang; Hongye Liu; Amir R Aref; Elena Ivanova; Cloud P Paweletz; Michaela Bowden; Chensheng W Zhou; Grit S Herter-Sprie; Jessica A Sorrentino; John E Bisi; Patrick H Lizotte; Ashley A Merlino; Max M Quinn; Lauren E Bufe; Annan Yang; Yanxi Zhang; Hua Zhang; Peng Gao; Ting Chen; Megan E Cavanaugh; Amanda J Rode; Eric Haines; Patrick J Roberts; Jay C Strum; William G Richards; Jochen H Lorch; Sareh Parangi; Viswanath Gunda; Genevieve M Boland; Raphael Bueno; Sangeetha Palakurthi; Gordon J Freeman; Jerome Ritz; W Nicholas Haining; Norman E Sharpless; Haribabu Arthanari; Geoffrey I Shapiro; David A Barbie; Nathanael S Gray; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2017-11-03       Impact factor: 38.272

9.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Authors:  Sílvia Beà; Rafael Valdés-Mas; Alba Navarro; Itziar Salaverria; David Martín-Garcia; Pedro Jares; Eva Giné; Magda Pinyol; Cristina Royo; Ferran Nadeu; Laura Conde; Manel Juan; Guillem Clot; Pedro Vizán; Luciano Di Croce; Diana A Puente; Mónica López-Guerra; Alexandra Moros; Gael Roue; Marta Aymerich; Neus Villamor; Lluís Colomo; Antonio Martínez; Alexandra Valera; José I Martín-Subero; Virginia Amador; Luis Hernández; Maria Rozman; Anna Enjuanes; Pilar Forcada; Ana Muntañola; Elena M Hartmann; María J Calasanz; Andreas Rosenwald; German Ott; Jesús M Hernández-Rivas; Wolfram Klapper; Reiner Siebert; Adrian Wiestner; Wyndham H Wilson; Dolors Colomer; Armando López-Guillermo; Carlos López-Otín; Xose S Puente; Elías Campo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

10.  Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

Authors:  David Chiron; Peter Martin; Maurizio Di Liberto; Xiangao Huang; Scott Ely; Brian J Lannutti; John P Leonard; Christopher E Mason; Selina Chen-Kiang
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.